Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy

Hematology Journal

Volumn 4, Issue 3, 2003, Pages 198-207

  Kiladjian, Jean Jacques ^a,f   Gardin, Claude ^a   Renoux, Michel ^b   Bruno, Franck ^c   Bernard, Jean François ^a,d,e  

^a BEAUJON HOSPITAL   (France)

^b Renal Unit Hôpital de la Côte Basque   (France)

^c Stat'Aids   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f AVICENNE HOSPITAL   (France)

Author keywords

Leukemia; Myelofibrosis; Myeloproliferative disorder; Pipobroman; Polycythemia

Indexed keywords

BUSULFAN; PIPOBROMAN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BONE MARROW APLASIA; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; ERYTHROCYTOSIS; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; IDIOPATHIC DISEASE; LEUKEMIA; LEUKOCYTOSIS; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEGALOCYTOSIS; MYELOFIBROSIS; PANCYTOPENIA; POLYCYTHEMIA VERA; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SKIN MANIFESTATION; SOLID TUMOR; STOMACH PAIN; STROKE; SURVIVAL; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VASCULAR DISEASE;

ACTUARIAL ANALYSIS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYELOFIBROSIS; NEOPLASMS; PIPOBROMAN; POLYCYTHEMIA VERA; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 0037715410     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200250     Document Type: Article

References (40)

1. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulfan: retrospective study from one center. Br J Haematol 1985; 61: 657-666.
2. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132-143.
3. 32P between 1969 and 1981. Semin Hematol 1997; 34: 6-16.
4. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997; 89: 2319-2327.
5. Haanen C, Mathe G, Hayat M. Treatment of polycythaemia vera by radiophosphorus or busulfan: a randomized trial. Br J Cancer 1981; 44: 75-80.
6. Gilbert HS. Problems relating to control of polycythemia vera: the use of alkylating agents. Blood 1968; 32: 500-505.
7. Higuchi T, Okada S, Mori H, Nikura H, Omine M, Terada H. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer 1995; 75: 471-477.
8. Donovan PB, Kaplan ME, Goldberg JD, Tatarsky I, Najean Y, Silberstein EB et al. Treatment of polycythaemia vera with hydroxyurea. Am J Hematol 1984; 17: 329-334.
9. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988; 41: 375-381.
10. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34: 17-23.
11. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370-3377.
12. Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 2000; 109: 141-149.
13. Streiff M, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 2002; 99: 1144-1149.
14. Monto RW, Tenpas A, Battle JF, Rohn RJ, Louis J, Louis NB. A-8103 in polycythemia. JAMA 1964; 190: 833-836.
15. Bohnel J, Stacher A. On the effect of a cytostatic drug agent in chronic myelosis and polycythemia. Wien Med Wochenschr 1968; 118: 721-723.
16. Bilski-Pasquier G, Blanc C, Bousser J. Traitement de la polycythemie de Vaquez par le 1-4 bis 53 bromopropionyl piperazine. Etude de 36 cas. Presse Med 1968; 41: 1953-1956.
17. Petti MC, Spadea A, Avvisati G, Spadea T, Latagliata R, Montefusco E et al. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). Leukemia 1998; 12: 869-874.
18. Passamonti F, Brusamolino E, Lazzarino M, Barate C, Klersy C, Orlandi E et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 2000; 85: 1011-1018.
19. Modan B, Lilienfeld AH. Polycythemia vera and leukemia. The role of radiation treatment. A study of 1222 patients. Medicine (Baltimore) 1965; 44: 305-344.
20. 32P (based on a series of 296 patients). Blood 1968; 32: 536-548.
21. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand 1962; 44: 155-157.
22. Brusamolino E, Salvaneschi L, Canevari A, Bernasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. J Clin Oncol 1984; 2: 558-561.
23. Bernard JF, Renoux M, Dhermy D, Lallemand R, Boivin P. Traitement de la polyglobulie primitive de Vaquez par le pipobroman. Résultats obtenus chez 63 malades traités entre 1969 et 1977. Nouv Press Med 1978; 7: 3527-3530.
24. Bernard JF, Renoux M, Turlure P, Gardin C, Briere J, Boivin P. Efficacy trial (1969-1991) of pipobroman as first treatment of polycythemia vera. A long-term study of 165 patients [abstract]. Br J Haematol 1994; 87: 144.
25. Wasserman LR. The management of polycythaemia vera. Br J Haematol 1971; 21: 371-376.
26. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12: 339-351.
27. Pearson TC, Wetherley-Mein G. The course and complications of idiopathic erythrocytosis. Clin Lab Haematol 1979; 1: 189-196.
28. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
29. Institut National de la Santé et de la Recherche Médicale: statistiques de mortalité en France pour les années 1979 à 1998 - INSERM sc no. 8. Le Vesinet (78) - France (http://sc8.vesinet.inserm.fr:1080/)
30. Pearson TC, Messinezy M. The diagnostic criteria of polycythaemia rubra vera. Leukemia Lymphoma 1996; 22: 87-93.
31. Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R et al. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Neth J Med 1999; 54: 46-62.
32. Kiladjian JJ, Dubernet E, Bruno F, Boivin P, Renoux M, Bernard JF. Idiopathic erythrocytosis: long-term outcomes of 39 patients treated with pipobroman in a prospective study [abstract]. Blood 2001; 98: 629a.
33. Pahl HL. Towards a molecular understanding of polycythemia rubra vera. Eur J Biochent 2000; 267: 3395-3401.
34. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
35. Boivin P, Bernard JF. Polycythaemia and hyperparathyroidism: a fortuitous association?. Eur J Haematol 1992; 49: 153-155.
36. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002; 76: 133-145.
37. Berk PD, Wasserman LR, Fruchtman SM, Goldberg J. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI (eds). Polycythemia Vera and The Myeloproliferative Disorders. Saunders: Philadelphia, PA, 1995, pp 166-194.
38. Ulich TR, del Castillo J, Senaldi G, Kinstler O, Yin S, Kaufman S et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996; 87: 5006-5015.
39. Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG et al. A model of myelofibrosis and osteosclerosis in mice induced by over expressing thrombopoietin (mpl-ligand): reversal of disease by bone marrow transplantation. Blood 1996; 88: 402-409.
40. Tubiana M, Attie E, Parmentier C. Le devenir des polyglobulies essentielles traitées par le phosphore radioactif. à propos d'une série de 303 malades suivis pendant 12 à 24 ans. Nouv Presse Med 1975; 4: 1781-1786.